Trial
NCT01991210
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Ovarian Cancer
Intervention
DNIB0600A
Why stopped
The primary objective of PFS did not meet pre-specified criteria.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-08-21